Durect Net Debt Over Time
| DRRX Stock | USD 0.79 0.01 1.28% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Durect Performance and Durect Correlation. Durect |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Durect. If investors know Durect will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Durect listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.64) | Revenue Per Share 0.284 | Quarterly Revenue Growth 0.043 | Return On Assets (0.40) | Return On Equity (3.00) |
The market value of Durect is measured differently than its book value, which is the value of Durect that is recorded on the company's balance sheet. Investors also form their own opinion of Durect's value that differs from its market value or its book value, called intrinsic value, which is Durect's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Durect's market value can be influenced by many factors that don't directly affect Durect's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Durect's value and its price as these two are different measures arrived at by different means. Investors typically determine if Durect is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Durect's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Debt Analysis
Compare Durect and related stocks such as Shuttle Pharmaceuticals, Mallinckrodt Plc, and Organogenesis Holdings Net Debt Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SHPH | 698.7 K | 698.7 K | 698.7 K | 698.7 K | 698.7 K | 698.7 K | 698.7 K | 698.7 K | 698.7 K | 698.7 K | 698.7 K | 474.1 K | (7.7 M) | (1.5 M) | (1.6 M) |
| ORGO | 48.9 K | 48.9 K | 48.9 K | 48.9 K | 48.9 K | 48.9 K | (1 M) | (25.9 K) | 38 M | 40.4 M | 377 K | 18.4 M | 21.3 M | 15.5 M | 16.3 M |
| TKNO | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (3.3 M) | (75.6 M) | 74 K | 2 M | 2.1 M |
| SNOA | (764 K) | (112 K) | (6 M) | (5.3 M) | (6 M) | (7.4 M) | (17.1 M) | (9.5 M) | (3.2 M) | (2.2 M) | (1.5 M) | (6 M) | (3 M) | (2.5 M) | (2.6 M) |
| LFCR | (13.7 M) | 36.8 M | 30.6 M | 20.1 M | 28.4 M | 52.1 M | 48.6 M | 70 M | 151.4 M | 220.8 M | 220.1 M | 151.5 M | 151.4 M | 121.9 M | 128 M |
| RDHL | (14.1 M) | (14.1 M) | (16.8 M) | (11.9 M) | (5.9 M) | (21.5 M) | (53.8 M) | (16.5 M) | (29 M) | (25.2 M) | 57.6 M | 58.3 M | 102.7 M | (4.4 M) | (4.2 M) |
| COLL | (6.6 M) | (6.6 M) | (6.6 M) | (6.6 M) | 11.4 M | (88.9 M) | (149.1 M) | (117.2 M) | (135.1 M) | (148.4 M) | 92.5 M | 72.3 M | 699.1 M | 435.3 M | 457.1 M |
| NBIX | (9.7 M) | (50.1 M) | (63.8 M) | (44.8 M) | (31 M) | (74.2 M) | (83.3 M) | 114.9 M | 246.8 M | 383.2 M | (388.7 M) | 99.6 M | 169.4 M | 177.3 M | 186.2 M |
| IRWD | (59.5 M) | (86.6 M) | (136.1 M) | 103.5 M | 103 M | 120.2 M | 318.8 M | 274.4 M | 240.8 M | 254.2 M | 91.1 M | (144.3 M) | (240.3 M) | 623.4 M | 654.6 M |
| ALKS | (2.8 M) | 360.9 M | 272 M | 196.7 M | 133.9 M | 168.8 M | 97.3 M | 90.1 M | 12.5 M | 73.4 M | 2 M | (41.7 M) | 797 K | (85.3 M) | (81 M) |
| AVDL | (13.4 M) | 607 K | 34.1 M | 79.1 M | 78.7 M | (63.9 M) | (38.4 M) | (16.3 M) | 106.5 M | 114.9 M | 58.8 M | 94.3 M | 57 M | 4.2 M | 4 M |
| AQST | 29.4 M | 29.4 M | 29.4 M | 29.4 M | 29.4 M | 29.4 M | 29.4 M | 28.1 M | (13.4 M) | 11 M | 8.7 M | 28.4 M | 28.8 M | 9.4 M | 13.1 M |
| EVOK | (865.9 K) | (865.9 K) | 863.8 K | (21.2 M) | (9.8 M) | (4.3 M) | (9 M) | (7.7 M) | (5.3 M) | (5.5 M) | (2.8 M) | (4.1 M) | (4.7 M) | 260.6 K | 273.6 K |
Durect and related stocks such as Shuttle Pharmaceuticals, Mallinckrodt Plc, and Organogenesis Holdings Net Debt description
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.My Equities
My Current Equities and Potential Positions
| Durect | DRRX |
| Classification | Pharmaceutical Products |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 0.79
Additional Tools for Durect Stock Analysis
When running Durect's price analysis, check to measure Durect's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Durect is operating at the current time. Most of Durect's value examination focuses on studying past and present price action to predict the probability of Durect's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Durect's price. Additionally, you may evaluate how the addition of Durect to your portfolios can decrease your overall portfolio volatility.